AbbVie: A new company with a rich heritage

Since January 1st 2013, AbbVie is an independent, global biopharmaceutical company, which was created after its separation from Abbott and focuses on the development of advanced treatments for some of the most complex and serious diseases.

The name AbbVie derives from two components. The first component "Abb", represents the strong legacy that carries with it, while the second, "Vie", comes from the Latin root of the word "life" and underlines the commitment of AbbVie to improve the lives of patients.

AbbVie combines the passion of an innovative biotechnology company with the expertise and 125years of experience of a renowned leader in the field of medicine, developing and ensuring access to innovative and effective treatments to patients around the world.

Patients at the centre

Constantly seeking the deep understanding of patients’ needs, AbbVie offers a broad range of innovative biologics, in immunology, renal disease, neuroscience, hepatitis C (HCV) and oncology.

Furthermore, through honest and good collaboration with qualified experts, academics and clinicians, physicians, patient associations and government members, AbbVie is focused towards innovation and constantly searches for solutions that will make a difference for patients, improving their quality of life and ensuring healthcare sustainability.

People. Passion. Possibilities.

Globally, AbbVie employs approximately 21,000 employees and operates in more than 170 countries; while in Greece has about 100 highly qualified employees in various disciplines who all share a common goal: make a substantial difference in patients' lives.

Supporting the Greek community

In the context of Social Responsibility program, AbbVie constantly contributes in the Greek economy and by giving the mark of a company that sets people as a first priority, actively supports social housing and day centres as part of the implementation of the program of Praksis, SYN sto PLIN, through a wide range of actions, events and volunteering.